Open App →
Back to News Feed
PR Newswire November 18, 2026 positive

Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach

AI / LLM
<p>EC approval follows recent U.S. FDA approval of Biocon's pertuzumab biosimilar Provides an additional treatment option for patients with HER2-positive breast cancer and may support more sustainable healthcare systems in Europe The milestone further strengthens Biocon's growing oncology...</p>
Read original article ↗

Related Articles

ACTO AI Roleplay Integration with Veeva Vault CRM via X-Pages Now Available for Field Teams to Rehearse Each HCP Conversation Before It Happens

Sales reps and MSLs can launch ACTO CxZone with one click from their planning screens, practice with an HCP avatar groun

PR Newswire · November 18, 2026

Die ACTO AI-Rollenspielintegration mit Veeva Vault CRM über X-Pages ist jetzt für Außendienstmitarbeiter verfügbar, um jedes Gespräch mit medizinischem Fachpersonal vorab zu üben.

Vertriebsmitarbeiter und MSLs können ACTO CxZone mit einem Klick von ihren Planungsbildschirmen aus starten, mit einem H

PR Newswire · November 18, 2026

Gopuff Joins the Swish Network to Expand Targeted, Measurable Product Sampling

Partnership gives brands more ways to reach high-potential customers through Gopuff, with the flexibility to activate ca

PR Newswire · November 18, 2026